ESMO 2021 Guardant Health View Data Recognizing the Use of Guardant360® Liquid Biopsy for Complete Cells to Lead Recurrent Cancer Treatment Options

0
13
ESMO 2021 Guardant Health View Data Recognizing the Use of Guardant360® Liquid Biopsy for Complete Cells to Lead Recurrent Cancer Treatment Options

Guardant INFORM™ Liquid Biopsy Dataset Shows No Clear Standard of Care and Unmet Need for Patients with HER2+ Metastatic Colorectal Cancer

ePoster

Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study

Presenter

Story Highlights


  • “While precision oncology has made a meaningful difference in improving clinical outcomes for highly prevalent cancers, such as non-small cell lung, colorectal, and breast, there remains a subset of patients who don’t respond to currently available treatments,” said Craig Eagle, MD, Guardant Health Chief Medical Officer. “It is gratifying to be able to work with the oncology community to analyze the molecular information generated from our liquid biopsy tests to continue to increase our understanding of possible new targets and more personalized treatments which can potentially improve overall survival of these hard-to-treat cancers in a more meaningful way.”


  • Title

439P

John Strickler

Guardant360® Liquid Biopsy Reveals Molecular Insights Impacting Outcomes in Patients with Unresectable and Early-Onset (<50 years) Metastatic Colorectal Cancer

Title

ePoster

Presenter

Molecular features in liquid biopsy of early (EO) and late-onset colorectal cancer (LO)

500P

503P

Manuel Benavides

Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR)

Julia Alcaide-Garcia